70462-58-7

Basic information

• Product Name: L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-, phenylmethyl ester
• CAS NO: 70462-58-7
• Molecular Formula: C26H32N2O5
• Molecular Weight: 452.55
• Mol File: 70462-58-7.mol

Chemical Properties

• CAS DataBase Reference: L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-, phenylmethyl ester(70462-58-7)
• EPA Substance Registry System: L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-, phenylmethyl ester(70462-58-7)

Safety Data

• Hazardous Substances Data: 70462-58-7(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 124980-30-9 N-carbobenzoxy-L-proline phenylmethyl ester 
• 24608-52-4 tert-butyl chloroformate 
• 38017-89-9 t-butyloxycarbonyl-L-phenylalanyl-L-proline methyl ester 
• 100-51-6 benzyl alcohol 
• 67729-36-6 Boc-Phe-O-COO-isoBu 
• 41324-66-7 H-Pro-OBzl 
• 16652-71-4 benzyl (2S)-2-pyrrolidinecarboxylate hydrochloride 
• 119206-32-5 C₁₉H₂₇NO₆ 
• 119153-87-6 (C₅H₉O₂)C₉H₉NO(O)(CO₂C₂H₅) 

Downstream Products

• 98908-44-2 N-benzyloxycarbonyl-L-tyrosyl-L-valyl-L-prolyl-L-leucyl-L-phenylalanyl-L-proline benzyl ester 
• 98908-42-0 N-(tert-bytyloxycarbonyl)-L-valyl-L-prolyl-L-leucyl-L-phenylalanyl-L-proline benzyl ester 
• 95716-19-1 N-(tert-butyloxycarbonyl)-L-leucyl-L-phenylalanyl-L-proline benzyl ester 
• 98925-63-4 L-tyrosyl-L-valyl-L-prolyl-L-leucyl-L-phenylalanyl-L-proline 
• 124456-05-9 L-valyl-L-prolyl-L-leucyl-L-phenylalanyl-L-proline benzyl ester hydrochloride 
• 87297-14-1 (S)-1-((S)-2-((benzyloxy)carbonyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-aminium chloride 
• 128234-82-2 BOCPheΨProOBz 
• 51644-77-0 H-Phe-Pro-OBzl 

Relevant articles and documents

Synthesis of 5(S)-Methyl-L-Proline Containing Peptidomimetic Compounds and their In Vitro Evaluation for Dipeptidyl Peptidase-4 Inhibition

Background: Type 2 diabetes mellitus (T2DM), which is the epidemic of the 21st century, has affected millions of people worldwide. Traditional methods available for the treatment are associated with various side effects. Among the newer therapies, DPP-4 (Dipeptidyl peptidase-4) inhibition has been a promising therapy for the past decade with the scope of further development, especially in peptidomimet-ics. Objective: 5(S)-methyl-L-proline containing peptidomimetic compounds were designed in the previous work. The designed compounds were synthesized and characterized by spectral methods, such as mass spectrometry,1H NMR, and13C NMR (Nuclear magnetic resonance) spectroscopy. The purity of the final compounds was determined by high-performance liquid chromatography (HPLC). The synthesized compounds were in vitro evaluated for their DPP-4 inhibitory activity. Methods: Compounds were peptide in nature and were synthesized using the conventional synthesis ap-proach, where peptide synthesis was done using an acid-amine coupling reagent. They were evaluated through fluorimetric enzyme-based assay using a DPP-4 inhibitor screening kit. Moreover, the CLARIO-star microplate reader instrument was used to measure fluorescence. Results: 5(S)-methyl-L-proline containing 13 compounds were synthesized. All of them were characterized for structural integrity using spectral methods. They had HPLC purity of more than 95% and were evaluated for DPP-4 inhibition. Compounds 1, 7, 10, 11, 14 and 17 were found to have good inhibition than others. These compounds were further evaluated at different concentrations to develop a linear corre-lation coefficient (R2). Conclusion: Six compounds were found to have good DPP-4 inhibition, hence it further opens the possi-bility of developing DPP-4 inhibitor-containing 5(S)-methyl-L-proline.

Inhibition of urease enzyme activity by urea and thiourea derivatives of dipeptides conjugated 2, 3-dichlorophenyl piperazine

Objective: Studies on enzyme inhibition remain an important area of pharmaceutical research since these studies have led to the discoveries of drugs used in a variety of physiological conditions. In search of novel urease enzyme inhibitors, four dipeptide

An improved route for the synthesis of Rolloamide B

A high yielding method for the synthesis of the cyclic heptapeptide Rolloamide B has been described. An effective isobutyl chloroformate (IBCF) mediated direct coupling reaction was introduced to improve the synthetic route towards Rolloamide B. Furthermo

Structure-Based Rationale Design and Synthesis of Aurantiamide Acetate Analogues - Towards a New Class of Potent Analgesic and Anti-inflammatory Agents

A series of new aurantiamide acetate analogues were synthesized by modifying its N-terminal substitution and the amino acid residue. The structure of all these compounds was established on the basis of analytical and spectral studies. All the new derivatives were evaluated in vivo for their analgesic activity by tail flick method in mice and anti-inflammatory activity against carrageenan-induced oedema in albino rats at different doses (25, 50 and 100mg/kg body weight). All the compounds exhibited significant pharmacological activity with no ulcerogenic liability. In particular, pentapeptides and tricosamers (30 amino acids) containing analogues have demonstrated high potency than the reference standards. These compounds hold promise for further development.

Design and synthesis of tryptophan containing peptides as potential analgesic and anti-inflammatory agents

A new series of smaller peptides with tryptophan at C-terminal and varying N-protected amino acids/peptides were designed, synthesized and characterized by analytical and spectroscopic techniques. Analgesic and anti-inflammatory properties of these peptides were carried out in vivo using tail-flick method and carrageenan-induced paw edema method, respectively, at different doses and different time intervals. Most of the peptides synthesized displayed enhanced activity, and particularly tetra and hexapeptides 29-31 were found to be even more potent than the reference standards used. Moreover, some peptides have exhibited promising activity even after 24h of administration, whereas the reference standards were active only up to 3h. Further, the compounds did not present any ulcerogenic liability.

Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP

We report the systematic rational design and synthesis of new monovalent Smac mimetics that bind preferentially to the BIR2 domain of the anti-apoptotic protein XIAP. Characterization of compounds in vitro (including 9i; ML101) led to the determination of key structural requirements for BIR2 binding affinity. Compounds 9h and 9j sensitized TRAIL-resistant breast cancer cells to apoptotic cell death, highlighting the value of these probe compounds as tools to investigate the biology of XIAP.

Synthesis and kinetics of oxidation of some dipeptides with anodically generated manganese(III) sulphate: Mechanistic study

Dipeptides (DP) namely phenylalanyl-proline (Phe-Pro), isoleucyl-proline (Ile-Pro), and leucyl-proline (Leu-Pro) were synthesized by classical solution method and characterized. The kinetics of oxidation of these DP by Mn(III) have been studied in the presence of sulphate ions in acidic medium at 26°C. The reaction was followed spectrophotometrically at λmax = 500 nm. A first-order dependence of rate on both [Mn(III)]0 and [DP]0 was observed. The rate is independent of the concentration of reduction product, Mn(II), and hydrogen ions. The effects of varying dielectric constant of the medium and addition of anions such as sulphate, chloride, and perchlorate were studied. The activation parameters have been evaluated using Arrhenius and Eyring plots. The oxidation products were isolated and characterized. A mechanism involving the reaction of DP with Mn(III) in the rate-limiting step is suggested.

Molecular design and structure - Activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664

A series of structurally novel small molecule inhibitors of human α-thrombin was prepared to elucidate their structure-activity relationships (SARs), selectivity and activity in vivo. BMS-189664 (3) is identified as a potent, selective, and orally active reversible inhibitor of human α-thrombin which is efficacious in vivo in a mouse lethality model, and at inhibiting both arterial and venous thrombosis in cynomolgus monkey models.

Hydrophobicity Dependence of Oxidation of Tetrapeptides of Elastin Sequences with Mn(III): Synthesis, Characterization, Kinetics, and Mechanistic Study

The analogues of elastin sequences, glycyl-glycyl-alanyl-proline (GGAP), glycyl-glycyl-phenylalanyl-proline (GGFP), and glycyl-glycyl-isoleucyl-proline (GGIP) were synthesized by classical solution phase method and characterized. The kinetics of oxidation of these tetrapeptides (TETP) by Mn(III) has been studied in the presence of sulphate ions in acidic solution at 25 deg C. The reaction was followed spectrophotometrically at λmax = 500 nm. A first-order dependence of rate on both [Mn(III)] and [TETP] was observed. The rate is independent of the concentration of the reduction product, Mn(II), and hydrogen ions. The effects of varying the dielectric constant of the medium and addition of anions such as sulphate, chloride, or perchlorate were studied. Activation parameters have been evaluated using Arrhenius and Eyring plots. The oxidation products were isolated and characterized. A mechanism involving the reaction of TETP with Mn(III) in the rate-limiting step is suggested. An apparent correlation was noted between the rate of oxidation and the hydrophobicity of these sequences, where increased hydrophobicity results in increased rate of oxidation.

Butylstannonic acid catalyzed transesterification of carboxylic esters

Butylstannonic acid is used as catalyst for transesterification of various carboxylic eaters. This method is also applicable to acetylation/deacetylation of alcohols.